Ajit Singh
Partner @ Artiman Ventures
San Francisco, United States
Ajit Singh is a Series A investor at Artiman Ventures in San Francisco focused on Health Care and Health Diagnostics. Ajit Singh has 2 current jobs as Partner at Artiman Ventures and Adjunct Professor at Stanford University School of Medicine. Additionally, Ajit Singh has had 2 past jobs including Lead Director at Max Healthcare.Prior to joining Artiman, Ajit was the President and CEO of BioImagene (acquired by Roche), a Digital Pathology company. BeforeBioImagene, Ajit spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology and Medical Informatics business of Siemens Healthcare. Prior roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research artificial intelligence, robotics, computer vision, and image analysis. During this time, he concurrently served on the faculty at Princeton University.Ajit has a Ph.D. in Computer Science from Columbia University, a master's degree in Computer Engineering from Syracuse University, and a bachelor's degree in Electrical Engineering from Banaras Hindu University, India. He has published two books and numerous refereed articles and holds five patents.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Ajit Singh invests in
Stages Ajit Singh invests in
Countries Ajit Singh invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (31%)
- Health Diagnostics 5 (31%)
- Biotechnology 4 (25%)
- Medical 3 (19%)
- Manufacturing 2 (13%)
Stage
- Series A 6 (38%)
- Series B 2 (13%)
- Venture - Series Unknown 2 (13%)
- Series C 1 (6%)
- Series E 1 (6%)
Country
- United States 5 (31%)
- India 3 (19%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test. The company combines artificial intelligence with insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer bloodtests. | $100M / Venture - Series Unknown / Jan 01, 2025 | ||
| Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100M / Series E / Mar 01, 2022 | ||
| Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100M / Series C / Apr 05, 2019 | ||
| Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $100.8M / Series C / Apr 05, 2019 | ||
| TeraPore's cutting edge technology facilitates rapid and efficient purification of biological fluids. Combining uniform pores with large pore densities enables purification of high-value products with fast processing times. Please contact us for more information. | $6M / Series A / Mar 06, 2018 | ||
| OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment andcure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer. | $6M / Series A / Sep 06, 2017 | ||
| CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures. | $22.5M / Venture - Series Unknown / Jan 05, 2017 | ||
| Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs. | $12M / Series B / Dec 02, 2016 | ||
| Aditazz designs and delivers next-generation healthcare facilities by integrating new design, technology and manufacturing techniques. Based in Silicon Valley, the company brings together experts and innovations from the worlds of semiconductor design, computer science, architecture, systems and structural engineering, modular manufacturing andassembly, and healthcare planning and operations. It has created a new generation of tools and technologies that results in dramatic increases in building construction speed, flexibility, predictability, cost-savings and ultimately improved healthcare - all while maintaining the highest degree of aesthetic and functional elegance. Aditazz received funding from Artiman Ventures and is a winner of Kaiser Permanente's 2012 'Small Hospital, Big Idea' design competition. | Series B / Oct 12, 2016 | ||
| MedECube is an asset-less firm in the healthcare sector that helps patients get access to doctors in major hospitals and clinics, including emergency care. MedECube offers demand side and supply side services by leveraging existing healthcare assets, to address systemic gaps in healthcare.Backed by Artiman Ventures, a Silicon Valley based venturecapital firm, medECUBE is an entirely new approach to healthcare delivery – where clinical coordination is at the center. | $4M / Series A / Mar 03, 2016 | ||
| See all 16 investments → | |||
Co-Investors
About Artiman Ventures
Artiman is an early-stage venture fund that seeks to invest in entrepreneurs that have the potential to disrupt multi-billion markets. The firm was established in 2000 and is headquartered in Palo Alto, California, United States.
Artiman Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ajit Singh
Partner
|
|||
Amit Shah
Founder & Partner
|
|||
Ramesh Radhakrishnan
Partner & Managing Director
|
|||
Brian Wilcove
Partner
|
|||
Mahmood Panjwani
Entrepreneur in Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ajit Singh invest in?
Ajit Singh invests primarily in Health Care, Health Diagnostics and Biotechnology startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ajit Singh?
Public channels for Ajit Singh include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ajit Singh last invest?
The most recent investment recorded for Ajit Singh closed in Jan 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
